Capital Research & Management Co recently announced the acquisition of new stake in Gilead Sciences, Inc. (NASDAQ:GILD). The institutional investor has increased its shareholding in the Healthcare company by 0.98% to 81.72 million shares with purchase of 0.79 million shares. This fresh investment now brings its stake to 6.56% valued currently at $6.26 billion. In addition, BlackRock Fund Advisors raised its holdings by 0.29 million to 81.32 million shares. And Capital Research & Management Co has lifted its position by 0.02% or 14039.0 shares – to 57.91 million shares.
With over 20.35 million Gilead Sciences, Inc. (GILD) shares trading Friday and a closing price of $80.33 on the day, the dollar volume was approximately $1.64 billion. The shares have shown a positive half year performance of 1.86% and its price on 12/15/23 lost nearly -1.77%. Currently, there are 1.25B common shares owned by the public and among those 1.25B shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 30 analysts who have offered their price forecasts for GILD have a consensus price objective of $89.37. The analysts have set the share’s price value over the next 12 months at a high of $116.00 and a low of $71.00. The average price target is 10.12% above its recent price level and a downside to the estimated low will see the stock lose -13.14% over that period. But an upside of 30.75% will see the stock hit the forecast high price target while median target price for the stock is $90.05.
Insiders at the company have transacted a total of 86 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 49 of these insider trades were purchases, accounting for 586,538 shares. Insider sales of the common stock occurred on 37 occasions, with total insider shares sold totaling 214,957 shares.
The top 3 mutual fund holders in Gilead Sciences, Inc. are Vanguard Total Stock Market ETF, American Funds Income Fund of Ame, and Vanguard 500 Index Fund. Vanguard Total Stock Market ETF owns 39.0 million shares of the company’s stock, all valued at over $2.99 billion. The company bought an additional 0.19 million shares recently to bring their total holdings to about 3.13% of the shares outstanding. American Funds Income Fund of Ame bought 0.7 million shares to see its total holdings expand to 34.44 million shares valued at over $2.64 billion and representing 2.76% of the shares outstanding. Vanguard 500 Index Fund bought 0.15 million shares to bring its total holdings to over 30.09 million shares at a value of $2.3 billion. Vanguard 500 Index Fund now owns shares totaling to 2.42% of the shares outstanding.
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) opened at $81.35, down -$0.43 from a prior closing price of $81.78. However, the script later moved the day high at 82.31, down -1.77%. The company’s stock has a 5-day price change of 1.66% and 6.23% over the past three months. GILD shares are trading -6.43% year to date (YTD), with the 12-month market performance down to -9.13% lower. It has a 12-month low price of $72.87 and touched a high of $88.29 over the same period. GILD has an average intraday trading volume of 6.00 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.64%, 3.48%, and 2.64% respectively.
Institutional ownership of Gilead Sciences, Inc. (NASDAQ: GILD) shares accounts for 85.31% of the company’s 1.25B shares outstanding. Mutual fund holders own 30.66%, while other institutional holders and individual stakeholders account for 55.61% and 1.33% respectively.
It has a market capitalization of $100.09B and a beta (3y monthly) value of 0.25. The stock’s trailing 12-month PE ratio is 17.23, while the earnings-per-share (ttm) stands at $4.66. The company has a PEG of 4.18 and a Quick Ratio of 1.20 with the debt-to-equity ratio at 1.12. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.07% over the week and 1.74% over the month.
Analysts forecast that Gilead Sciences, Inc. (GILD) will achieve an EPS of $1.63 for the current quarter, $1.65 for the next quarter and $6.67 for 2024. The lowest estimate earnings-per-share for the quarter is $1.5 while analysts give the company a high EPS estimate of $1.87. Comparatively, EPS for the current quarter was $1.67 a year ago. Earnings per share for the fiscal year are expected to decrease by -6.61%, and 7.59% over the next financial year. EPS should grow at an annualized rate of 4.12% over the next five years, compared to 0.73% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 30 brokerage firm advisors rate Gilead Sciences, Inc. (GILD) as a “Moderate Buy” at a consensus score of 2.20. Specifically, 12 Wall Street analysts polled rate the stock as a buy, while 15 of the 30 advise that investors “hold,” and 1 rated it as a “Sell.”
Looking at the support for the GILD, a number of firms have released research notes about the stock. Deutsche Bank stated their Hold rating for the stock in a research note on November 09, 2023, with the firm’s price target at $75.
